Hydroxyethyl starch and change in renal function in patients undergoing coronary artery bypass graft surgery  by Winkelmayer, Wolfgang C. et al.
Kidney International, Vol. 64 (2003), pp. 1046–1049
Hydroxyethyl starch and change in renal function in patients
undergoing coronary artery bypass graft surgery
WOLFGANG C. WINKELMAYER, ROBERT J. GLYNN, RAISA LEVIN, and JERRY AVORN
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School,
Boston, Massachusetts
Hydroxyethyl starch and change in renal function in patients
undergoing coronary artery bypass graft surgery.
Background. Several case reports and clinical lore have sug-
gested that exposure to the colloid hydroxyethyl starch may
impair renal function, but few studies have systematically ad-
dressed this issue, and several have produced conflicting results.
We sought to study the question in a formal analysis of post-
operative change in renal function in patients undergoing coro-
nary artery bypass graft (CABG) surgery.
Methods. We identified 238 consecutive patients who under-
went CABG surgery at a large academic medical center. Glo-
merular filtration rate (GFR) was estimated using the Cock-
roft-Gault formula at baseline as well as on postoperative days
3 and 5. Linear regression analysis was used to study the rela-
tion between changes in GFR and intraoperative hydroxyethyl
starch administration. Multivariate models controlled for po-
tential demographic, clinical, and surgery-related confounders.
Results. Hydroxyethyl starch use was independently associ-
ated with a reduction in GFR on both postoperative days 3
and 5, with GFR declining by 7.2 mL/min/1.73 m2 on day 3 per
unit of hydroxyethyl starch administered (95% CI, 1.7 to 12.7;
P  0.012), and by 6.6 mL/min/1.73 m2 on day 5 (95% CI, 1.2
to 11.9; P  0.018).
Conclusion. Intraoperative use of hydroxyethyl starch may
be associated with modest impairment in renal function in
patients undergoing CABG surgery. Randomized clinical trials
will be necessary to confirm these findings and to further inves-
tigate their clinical implications.
Hydroxyethyl starch is a widely used plasma substitute
in many clinical situations where volume replacement is
considered necessary. Clinicians often use hydroxyethyl
starch rather than alternative preparations because of the
perception that its volume effect is more long-lasting that
that achieved with crystalloid solutions [1], and because
of its lower cost compared to the other commonly used
colloid, human albumin. Clinical practice and opinion
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vary substantially on these points [1, 2]. Over the past
decade, several cases of acute kidney failure, or osmotic
nephrosis-like lesions in biopsy specimens, have been
reported and were thought to be related to hydroxyethyl
starch use in the affected patients [3–6]. To our knowl-
edge, only five systematic studies have been conducted to
address this question [7–11]. The populations studied were
quite heterogeneous: three studies (two retrospective and
one prospective) evaluated the effects of hydroxyethyl
starch exposure in kidney donors on renal function in
recipients [7–9], one study tested the effects of various
fluid replacement regimens on renal function in elderly
patients undergoing major abdominal surgery [10], and
one group studied patients in septic shock [11]. Another
experiment was done using an animal model [12]. The
results from these studies have been conflicting, with
some implicating hydroxyethyl starch use in deteriora-
tion of renal function, and others refuting this relation-
ship. All studies have involved small numbers of patients.
We sought to evaluate the association between hydroxy-
ethyl starch use and decline of renal function in a large
retrospective study of consecutive patients undergoing
coronary artery bypass graft (CABG) surgery.
METHODS
We reviewed the medical records of 238 consecutive
patients who underwent CABG surgery at a large teach-
ing hospital over 1 year. Those who underwent valvular
repair or replacement during the same surgical session
were not considered. An experienced medical chart ab-
stractor extracted the following demographic and clinical
covariates: age, gender, body surface area, type of admis-
sion (elective vs. nonelective), and preoperative mea-
sures (serum albumin level, creatinine, blood urea nitro-
gen, and use of catecholamines or an intra-aortic balloon
pump). We also assessed information about the proce-
dure itself (extracorporeal bypass time, lowest blood
temperature during surgery, and use and dose of intra-
operative albumin or hydroxyethyl starch). Only a single
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hydroxyethyl starch preparation was used at this institu-
tion during the study period (molecular weight, 670 kD;
molar substitution, 0.75). One unit of hydroxyethyl starch
contained 500 mL. We then assessed serum creatinine
on postoperative days 3 and 5 and applied the Cockroft-
Gault formula to estimate glomerular filtration rate (GFR)
prior to surgery, as well as on postoperative days 3 and 5.
[13] From this information, we calculated two outcomes
measures: (1) the differences between estimated GFR
at baseline and on day 3 after surgery, and (2) between
baseline and postoperative day 5, respectively.
As both of these measures were normally distributed,
we initially used simple linear regression to test for crude
relationships between each difference measure and intra-
operative hydroxyethyl starch use as well as the other
covariates. Multivariate linear regression was then used
to evaluate a possible association between intraoperative
hydroxyethyl starch use and difference in GFR while
controlling for other potential confounders. All indepen-
dent covariates were included in the final models without
a fixed significance threshold. Statistical tests were two-
sided and outcomes were regarded as significant at P 
0.05. All statistical analyses used the SAS for UNIX
software, version 8.1 (The SAS Institute, Inc., Cary, NC,
USA). The study was approved by the Institutional Re-
view Board of the Brigham and Women’s Hospital.
RESULTS
Of the 238 consecutive CABG patients initially identi-
fied, important covariate information was missing in 29,
leaving 209 patients for analysis. Only one patient died
in the hospital, 17 days after surgery. During their proce-
dures, 114 patients were not exposed to hydroxyethyl
starch, and 95 were, receiving a mean 1.3 units of hydroxy-
ethyl starch (SD, 0.52). Baseline covariate information
for the groups exposed and not exposed to hydroxyethyl
starch can be found in Table 1. On postoperative days
3 and 5, the GFR estimates among patients who did not
receive any hydroxyethyl starch were 90.0 mL/min/1.73
m2 (SD  45.9) and 86.9 mL/min/1.73 m2 (SD  49.6),
respectively. Univariate analyses indicated that patients
who received any dose of hydroxyethyl starch during sur-
gery had a greater body surface area (P  0.014), longer
intraoperative bypass time (P  0.014), and were more
likely to be male (P 0.036) compared to those patients
who were not exposed to hydroxyethyl starch.
Multivariate analyses revealed that intraoperative ex-
posure to hydroxyethyl starch was associated with a decline
in renal function from baseline after controlling for all
available potential confounders. By postoperative day 3,
estimated GFR declined by a mean 7.2 mL/min/1.73 m2
per unit of hydroxyethyl starch administered (95% CI,
1.7 to 12.7) (Fig. 1). By postoperative day 5, estimated
Table 1. Characteristics of the study population
Patients who received
No hydroxy- Any hydroxy-
Characteristic N ethyl starch ethyl starch
(row %) (N  114) (N  95) P value
Age
40–49 6 (5.3%) 9 (9.5%)
50–59 11 (9.7%) 17 (17.4%)
60–69 29 (25.4%) 25 (26.3%)
70–79 55 (48.3%) 32 (33.7%)
80–89 13 (11.4%) 12 (12.6%) 0.056
Gender
Female 43 (37.7%) 23 (24.2%)
Male 71 (62.3%) 72 (75.8%) 0.036
Mode of admission
Elective 35 (30.7%) 31 (32.6%)
Nonelective 79 (69.3%) 64 (67.4%) 0.765
Serum creatinine mg/dL
1.0 69 (60.5%) 61 (64.2%)
1.0–2.0 37 (32.5%) 28 (29.5%)
2.0 8 (7.0%) 6 (6.3%) 0.644
Baseline estimated GFR
mL/min/1.73 m2
90 37 (32.5%) 40 (42.1%)
60–90 40 (35.1%) 30 (31.6%)
30–60 29 (25.4%) 20 (21.1%)
30 8 (7.0%) 5 (5.3%) 0.167
Serum albumin mg/dL
3.5 24 (21.1%) 17 (17.9%)
3.5–4.0 43 (37.7%) 34 (35.8%)
4.0 47 (41.2%) 44 (46.3%) 0.467
Body surface area m2
2.0 81 (71.0%) 52 (54.7%)
2.0 33 (29.0%) 43 (45.3%) 0.014
Hematocrit %
30 35 (30.7%) 22 (23.2%)
30 79 (69.3%) 73 (76.8%) 0.223
Catecholamine therapy
Yes 51 (44.7%) 50 (52.6%)
No 63 (55.3%) 45 (47.4%) 0.255
Intra-aortic balloon pump
Yes 20 (17.5%) 16 (16.8%)
No 94 (82.5%) 79 (83.2%) 0.894
Intraoperative bypass 79.3 89.5
time minutes (SD  30.9) (SD  39.7) 0.014
Lowest intraoperative 29.8 29.2
temperature C (SD  3.3) (SD  3.5) 0.287
Abbreviations are: GFR, glomerular filtration rate; SD, standard deviation.
GFR was 6.6 mL/min/1.73 m2 lower than baseline per
unit administered (95% CI, 1.2 to 11.9).
We next sought to determine whether any factors put
patients at particular risk of experiencing this outcome
after hydroxyethyl starch use and tested for effect modi-
fication by several covariates, including age, baseline
GFR, and intraoperative bypass time. None of the inter-
action terms were found to be statistically significant.
DISCUSSION
In this study of 238 consecutive patients undergoing
CABG surgery, we found that intraoperative use of hy-
droxyethyl starch was associated with a modest decline in
renal function at days 3 and 5 after surgery, with estimated
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Fig. 1. Difference in estimated glomerular filtration rate [per 500 mL
of hydroxyethyl starch received (in mL/min/m2)]. From multivariate
linear regression models controlling for age, gender, mode of admission,
baseline albumin, baseline estimated glomerular filtration rate, body
surface area, preoperative catecholamines, intraoperative bypass time,
lowest intraoperative temperature.
GFR declining by 7.2 mL/min/1.73 m2 per unit hydroxy-
ethyl starch applied by day 3 and by 6.6 mL/min/1.73 m2
by day 5. These findings were based on models that
controlled for a large number of patient characteristics
and descriptors of the duration and severity of the surgi-
cal procedure. Therefore, the estimated average loss of
renal function after exposure to 2 units of hydroxyethyl
starch is approximately 14 mL/min/1.73 m2. To put the
magnitude of these results into perspective, this was twice
as large as the difference in creatinine clearance found
after 6 years of enalapril vs. placebo exposure in normo-
tensive and normoalbuminuric patients with type 2 dia-
betes (3.6 mL/min) [14]. Similarly, the difference in de-
cline in GFR between patients with insulin-dependent
diabetes and diabetic nephropathy receiving enalapril
vs. metoprolol after 2 years of treatment was 5 mL/
min [15]. These and similar studies have been used for
generally accepted treatment recommendations and qual-
ity assurance programs designed to reduce even mild de-
grees of renal impairment [16].
The present study has certain limitations. While we
controlled for information on several important patient
characteristics and indicators of invasiveness or complex-
ity of the surgical procedure, we cannot exclude the possi-
bility that other confounding factors might have remained
unobserved or incompletely controlled, and therefore
were not accounted for adequately in our analyses. Such
a factor would need to be an early indicator or cause
of postoperative renal damage that would also make
anethesiologists more likely to administer patients hy-
droxyethyl starch. In addition, these data do not address
whether the observed decline in renal function is tempo-
rary or irreversible, or if there are any morphologic cor-
relates of the functional impairment. If the short-term
effects on renal function reported here are replicated in
long-term follow-up, it will be essential to also evaluate
the long-term consequences of hydroxyethyl starch ther-
apy on other domains of morbidity and on cost. Finally,
the study did not have sufficient power to evaluate clini-
cal factors that might modify the association between
hydroxyethyl starch exposure and renal function.
The present study adds to the scarce information avail-
able regarding the possible detrimental effect of hydroxy-
ethyl starch use and renal function. While there have
been several case reports that attributed functional or
morphologic damage to this agent [3–6], few systematic
studies have been available thus far. In a research letter
to Lancet, Legendre [7] reported an association between
hydroxyethyl starch exposure of organ donors and os-
motic nephrosis-like lesions in the transplant recipients.
They retrospectively compared 90 patients from a single
institution, but for two distinct time periods: one before
hydroxyethyl starch was made available for use in France
and a subsequent period where hydroxyethyl starch was
widely used. The appearance of osmotic nephrosis-like
lesions was observed more frequently during the latter
time period (80% vs. 14%; P  0.01). Similar histologic
findings were reported after aggressive isovolemic hemo-
dilution with hydroxyethyl starch in anaesthetized dogs
[12]. Cittanova et al [8] later investigated prospectively
whether hydroxyethyl starch use in brain-dead kidney
transplant donors was a determinant of renal function in
the organ recipient after transplantation. Twenty-seven
kidney donors were randomized to either a hydroxyethyl
starch gelatin regimen for fluid management, or to a
gelatin-only regimen. A significantly higher proportion
of kidney recipients in the hydroxyethyl starch group
required hemodialysis or hemodiafiltration in the first 8
days after transplantation compared to the gelatin group
(33% vs. 5%; P  0.029). In addition, at 10 days after
transplantation, serum creatinine concentrations were
significantly higher in recipients of kidneys of donors
randomized to the hydroxyethyl starch group compared
to the gelatin group (312 mol/L vs. 145 mol/L; P 
0.009). However, Deman, Peeters, and Sennesael [9]
failed to confirm these findings in a retrospective, multi-
center analysis of kidney transplant recipients that used
delayed graft function as the main outcome measure.
They did find that mean posttransplant serum creatinine
concentrations were higher in one of the hydroxyethyl
starch groups (molecular weight in kilodalton/degree of
substitution) (200/0.5) compared to the control group as
well as to a second hydroxyethyl starch group (450/0.7).
By 14 days posttransplantation, no difference was ob-
served among the three groups. These findings did not
appear to make use of multivariate analysis, and so pro-
vide only limited evidence.
Kumle at al [10] evaluated the effects of three different
intravascular volume replacement regimens on renal
function in 60 patients undergoing major abdominal sur-
gery: two hydroxyethyl starch preparations (70/0.5 and
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200/0.5) and modified gelatin. Creatinine clearance ap-
pears not to have differed among the three regimens
over the 3-day period of observation. Unfortunately,
data were not presented beyond this brief period, and
no test statistics were provided for the other functional
indicators studied (N-acetyl-	-glucosaminidase, 
1-micro-
globulin, and fractional sodium excretion). The small
sample size would have yielded only limited power to
detect any meaningful differences in outcomes.
Schortgen et al [11] conducted a randomized multicen-
ter study comparing the effects of hydroxyethyl starch
(200/0.66) and fluid-modified gelatin on renal function
in 129 patients with severe sepsis. They found that the
frequency of acute renal failure (42% vs. 23%; P 
0.028) and oliguria (56% vs. 37%; P  0.025) as well as
peak serum creatinine concentration (225mol/L vs. 169
mol/L; P 0.04) were higher in the hydroxyethyl starch
group than in the gelatin group. However, this study was
followed by considerable criticism. Serum creatinines
were higher in the hydroxyethyl starch group at baseline,
and critics argued that this chance difference should have
been accounted for in the data analysis [17–20].
The present study is the largest to date to evaluate a
possible association between hydroxyethyl starch expo-
sure and renal function. Our analysis of a cohort of
patients undergoing a frequently performed surgical pro-
cedure suggests that exposure to hydroxyethyl starch
may be associated with a decrement in renal function
independent of renal functional status at baseline. This
study points toward opportunities for future research
with important clinical implications. It seems necessary
to conduct a sufficiently large randomized controlled
trial to confirm these findings, to describe long-term ef-
fects, and to identify patients who are particularly suscep-
tible to this potentially important side effect of hydroxy-
ethyl starch use.
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